The April announcement of a biomarker-based diagnosis for Alzheimer's disease by the National Institute of Aging (NIA) and the Alzheimer's Association (AA) came with assurances that their recommendations were meant as a "research framework to investigate the Alzheimer's disease continuum, not as diagnostic criteria and explicitly not intended for clinical use." Read More
TEL AVIV, Israel – Long focused on powering its depth of technological knowhow to develop strong med tech, Israel is now increasingly looking toward biotech as a pillar of growth for its health care industry and for the economy as a whole. Read More
Ligand Pharmaceuticals Inc., of San Diego, said it intends to offer $650 million in convertible senior notes due 2023 in a private offering to qualified institutional buyers. Read More
Toolgen Inc., of Seoul, South Korea, presented data demonstrating that blocking a molecular pathway that down-regulates T-cell activity with the company's CRISPR/Cas9 gene editing platform results in increased T-cell receptor signaling in vitro and in improved antitumor activity when tested in a mouse glioblastoma tumor model. Read More
Onconano Medicine Inc.'s $11.7 million in series A money should let the company finish phase I trials with its imaging agent and bring a therapeutic candidate to IND-enabling studies, CEO Ravi Srinivasan told BioWorld, as the company works with a "phenomenon [that] has not been exploited so far, even though it's been well-known and well-established in the cancer field." Read More
The celebrated annual release of abstracts from the American Society of Clinical Oncology (ASCO) meeting claimed an early victim Thursday as shares of Jounce Therapeutics Inc. (NASDAQ:JNCE) fell 35.2 percent, closing at $11.45 for a loss of $6.22, after analysts began sifting through the data dump and found the company's update wanting. Read More
US Worldmeds LLC has landed the first FDA approval of a non-opioid treatment for the management of opioid withdrawal symptoms, giving U.S. doctors a tool that has long helped U.K. doctors provide relief to patients going off the powerful medicines. Read More
The Centers for Medicare & Medicaid Services opened a 30-day public comment period for its national coverage analysis of chimeric antigen receptor T-cell therapy for cancers. Read More
